ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors

Lin, Xuwen; Chen, Xi; Long, Xiang; Zeng, Chao; Zhang, Zhihan; Fang, Weiyi*; Xu, Ping*北京大学; 南方医科大学; 汕头大学
Respiratory Research2023-2-27DOI: 10.1186/s12931-023-02370-0
2被引15阅读
引用收藏
分享

摘要

BackgroundImmune checkpoint inhibitors (ICIs) are regarded as the most promising treatment for advanced-stage non-small cell lung cancer (aNSCLC). Unfortunately, there has been no unified accuracy biomarkers and systematic model specifically identified for prognostic and severe immune-related adverse events (irAEs). Our goal was to discover new biomarkers and develop a publicly accessible method of identifying patients who may maximize benefit from ICIs.MethodsThis retrospective study enrolled 138 aNSCLC patients receiving ICIs treatment. Progression-free survival (PFS) and severe irAEs were end-points. Data of demographic features, severe irAEs, and peripheral blood inflammatory-nutritional and immune indices before and after 1 or 2 cycles of ICIs were collected. Independent factors were selected by least absolute shrinkage and selection operator (LASSO) combined with multivariate analysis, and incorporated into nomogram construction. Internal validation was performed by applying area under curve (AUC), calibration plots, and decision curve.ResultsThree nomograms with great predictive accuracy and discriminatory power were constructed in this study. Among them, two nomograms based on combined inflammatory-nutritional biomarkers were constructed for PFS (1 year-PFS and 2 year-PFS) and severe irAEs respectively, and one nomogram was constructed for 1 year-PFS based on immune indices. ESCLL nomogram (based on ECOG PS, preSII, changeCAR, changeLYM and postLDH) was constructed to assess PFS (1-, 2-year-AUC = 0.893 [95% CI 0.837-0.950], 0.828 [95% CI 0.721-0.935]). AdNLA nomogram (based on age, change-dNLR, changeLMR and postALI) was constructed to predict the risk of severe irAEs (AUC = 0.762 [95% CI 0.670-0.854]). NKT-B nomogram (based on change-CD3+CD56+CD16+NKT-like cells and change-B cells) was constructed to assess PFS (1-year-AUC = 0.872 [95% CI 0.764-0.965]). Although immune indices could not be modeled for severe irAEs prediction due to limited data, we were the first to find CD3+CD56+CD16+NKT-like cells were not only correlated with PFS but also associated with severe irAEs, which have not been reported in the study of aNSCLC-ICIs. Furthermore, our study also discovered higher change-CD4+/CD8+ ratio was significantly associated with severe irAEs.ConclusionsThese three new nomograms proceeded from non-invasive and straightforward peripheral blood data may be useful for decisions-making. CD3+CD56+CD16+NKT-like cells were first discovered to be an important biomarker for treatment and severe irAEs, and play a vital role in distinguishing the therapy response and serious toxicity of ICIs.

学科与关键词

关键词
ImmuneAdverse eventsLung cancerBiomarkersNomogram
相关
加载中…
  • Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors
    Wang, Li; Ren, Zhixuan; Yu, Bentong; Tang, Jian*Journal of Translational Medicine, 2021, 19(1): 22.被引 12
  • The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
    Gao, Weitong; Liu, Qianqian; Zhou, Yang; Yang, Min; Yu, Yan*TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22: 15330338231206705.
  • Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer
    Cheng, M.; Lin, R.; Bai, N.; Zhang, Y.; Wang, H.; Guo, M.; Duan, X.; Zheng, J.*; Qiu, Z.*; Zhao, Y.*Clinical Radiology, 2023, 78(5): e377-e385.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Respiratory Research
发表日期
2023-02-27
卷期
第 24 卷, 第 1 期
页码
64
DOI
10.1186/s12931-023-02370-0
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81974460]; Shenzhen Science and Technology Innovation Commission Foundation [JCYJ20190809103203711]; Shenzhen Science and Technology Innovation Commission Foundation [JCYJ20210324105411031]; Shenzhen High Level Hospital Construction Fund [LCYJ2021022, LCYJ2021008]; Natural Science Foundation of Guangdong Province [2023A1515012460]

作者

  • L

    Lin, Xuwen (第一作者)

    shantou univ · peking univ

  • C

    Chen, Xi

    shantou univ · peking univ

查看全部 7 位作者收起作者
  • L

    Long, Xiang

    peking univ

  • Z

    Zeng, Chao

    peking univ

  • Z

    Zhang, Zhihan

    peking univ

  • F

    Fang, Weiyi (通讯)

    southern med univ

  • X

    Xu, Ping (通讯)

    peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417